title: Transgender Patients, Isotretinoin, and US Food and Drug Administration-Mandated Risk Evaluation and Mitigation Strategies: A Prescription for Inclusion.
authors.affiliation: Department of Dermatology, Kaiser Permanente, Pleasanton, California.
authors.forename: Kenneth A
authors.initials: KA
authors.lastname: Katz
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy*; D000075202:Contraindications; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D005260:Female; D033161:Government Regulation; D006297:Health Services Accessibility / Q000331:legislation & jurisprudence; D040361:Healthy People Programs / Q000331:legislation & jurisprudence*; D006801:Humans; D015474:Isotretinoin / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D011247:Pregnancy; D018570:Risk Assessment / Q000331:legislation & jurisprudence; D000073938:Risk Evaluation and Mitigation / Q000331:legislation & jurisprudence; D063106:Transgender Persons; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
chemical_list: D015474:Isotretinoin